Details for New Drug Application (NDA): 085079
✉ Email this page to a colleague
NDA 085079 describes PROCAN, which is a drug marketed by Parke Davis, Parkedale, and King Pharms, and is included in eight NDAs. Additional details are available on the PROCAN profile page.
The generic ingredient in PROCAN is procainamide hydrochloride. There are nine drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the procainamide hydrochloride profile page.
The generic ingredient in PROCAN is procainamide hydrochloride. There are nine drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the procainamide hydrochloride profile page.
Summary for 085079
| Tradename: | PROCAN |
| Applicant: | Parke Davis |
| Ingredient: | procainamide hydrochloride |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 085079
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | 500MG | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
